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The receptor-binding domain (RBD) in the surface (SU) subunit of gammaretrovirus envelope glycoprotein is critical for determining the host
receptor specificity of the virus. This domain is separated from the carboxy terminal C domain (Cdom) of SU by a proline-rich region. In this
study, we show that the Cdom region in the SU from subgroup C feline leukemia virus (FeLV-C) forms a second receptor-binding domain that is
distinct from its RBD, and which can independently bind to its host receptor FLVCR1, in the absence of RBD. Furthermore, our results suggest
that residues located in the C2 disulfide-bonded loop in FeLV-C Cdom are critical for SU binding to FLVCR1 and for virus infection. We propose
that binding of FeLV-C SU to FLVCR1 involves interaction of two receptor-binding domains (RBD and Cdom) with FLVCR1, and that this
mechanism of interaction is conserved for other gammaretroviruses. Our results could have important implications for designing gammaretrovirus
vectors that can efficiently infect specific target cells.
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the surface (SU) subunit of the viral envelope glycoprotein
(Env) with a specific host cell surface receptor, followed by
fusion of the virus and host cell membranes, which is mediated
by the transmembrane (TM) subunit of Env. For gammaretro-
viruses (γ-retroviruses), receptor binding and specificity is
controlled by the receptor-binding domain (RBD) located in the
N terminal 200–250 amino acids of γ-retrovirus SU (Battini et
al., 1992, 1995). The RBDs from murine leukemia virus (MLV)
and feline leukemia virus (FeLV) are highly conserved in
sequence and differ predominantly in distinct variable regions
defined as VRA, VRB and VRC (Battini et al., 1992; Fass et al.,
1997). These variable regions contain critical residues that
control receptor binding and specificity (Battini et al., 1998;
Brojatsch et al., 1992; Rigby et al., 1992; Tailor andKabat, 1997;
Tailor et al., 2000a). The RBD forms a distinct globular domain⁎ Corresponding author. The Hospital for Sick Children, Program in Cell
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doi:10.1016/j.virol.2007.09.011(Barnett et al., 2001; Fass et al., 1997) that is anchored to the
carboxy terminal C domain (Cdom) of MLVand FeLV SU, by a
proline-rich region (PRR) that has been suggested to form a
“hinge” structure. PRR and Cdom are also highly variable
between MLVs and FeLVs.
The intricate mechanism of how γ-retrovirus SUs bind to
their receptors and trigger the virus fusion mechanism has yet to
be fully elucidated. A histidine residue in a PHQ motif, located
in the N terminus of RBD, has been shown to be critical for
triggering virus fusion (Bae et al., 1997; Lavillette et al., 2000;
Zavorotinskaya and Albritton, 1999). Mutation or deletion of
this single residue disrupts virus fusion but not receptor binding.
Interestingly, infection of these fusion defective viruses (ΔH
viruses) can be rescued if soluble SU or RBD is provided in
trans (Barnett and Cunningham, 2001; Barnett et al., 2001;
Lavillette et al., 2001; Lavillette et al., 2000). For some ΔH
viruses, fusion can be activated in the presence of heterologous
soluble RBDs, but only if both the receptors for ΔH virus and
the soluble RBD are present. Subsequent studies have suggested
a model for MLV Env fusion activation that involves an initial
interaction of RBD with the host receptor followed by a second
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located in MLV Cdom (Barnett and Cunningham, 2001; Barnett
et al., 2001; Lavillette et al., 2001). This model is based on
studies using soluble ecotropic MLV RBD which can activate
fusion ofΔH amphotropic MLVwith the C2 loop substituted for
ecotropic C2 loop, and of MLVs with the RBD deleted (Barnett
and Cunningham, 2001; Barnett et al., 2001). However, a direct
interaction between RBD and the C2 loop containing Cdom has
yet to be demonstrated. Furthermore, the MLV fusion model is
inconsistent with other MLVs because soluble RBDs from
amphotropic and xenotropic MLV are unable to activate fusion
of any RBD deleted MLVs including RBD-deleted amphotropic
and xenotropic MLVs (Barnett and Cunningham, 2001). This
raises the possibility of an alternative mechanism of envelope–
receptor interaction for these γ-retroviruses.
Recent reports suggest that, in addition to RBD, the C
terminal domain of γ-retrovirus SU may also control receptor
recognition and virus infection. Studies characterizing SUs from
subgroup B FeLV and from pig endogenous retroviruses have
shown that the C terminal domain of these SUs control
recognition of receptor homologues from certain species
(Boomer et al., 1997; Faix et al., 2002; Gemeniano et al.,
2006; Sugai et al., 2001). Additional studies have shown that the
C2 loop in C terminal domain of FeLV-A and FeLV-T SUs
controls infection of target cells (Cheng et al., 2006).
In this study, we investigated the role of the Cdom region of
FeLV-C SU in binding to the FeLV-C receptor FLVCR1
(Quigley et al., 2000; Tailor et al., 1999), and in virus infection.
FLVCR1 has been identified as an exporter of heme and has been
suggested to be critical for development of erythroid progenitor
cells (Quigley et al., 2004). Hybrid Envs were generated
between FeLV-C Env and the closely related FeLV-A or -T Envs,
and subsequently tested for their ability to interfere with FeLV-C
infection, and to bind to and infect FLVCR1-expressing cells.
Our results suggest that FeLV-C Cdom forms a receptor-binding
domain that is distinct from FeLV-C RBD. Furthermore, we
show that Cdom is critical for efficient SU binding and for virus
infection. We propose that Cdom in FeLV-C SU functions as
second receptor-binding domain, which in addition to RBD,
interacts with the host receptor to initiate virus infection.
Results
To comprehensively ascertain the role of the C terminal
region of FeLV SU in receptor binding and virus infection, we
generated specific hybrid Envs and SUs between the closely
related Envs from FeLV-A, -C and -T, in which the C terminal
region encompassing PRR and C domain was substituted. These
FeLV Envs were selected for this study because first, their SUs
share 86–95% amino acid identity (Fig. 1A) yet they recognize
distinct receptors (Anderson et al., 2000; Mendoza et al., 2006;
Quigley et al., 2000; Tailor et al., 1999), and second, sequence
divergence between these Envs is primarily confined to VRA,
located in RBD, and to the C2 loop located in the C domain
(Cdom) (Fig. 1A). In this study, we focused on characterizing the
Cdom of FeLV-C SU for its role in binding to FLVCR1, and its
role in virus infection of murine Mus dunni tail fibroblast(MDTF) cells expressing human FLVCR1 (MDTF/hCR1). We
initially generated the CA and CT hybrid Envs that are spliced
just downstream of VRB (Figs. 1A and B). These Envs contain
the first 155 residues of FeLV-C RBD (RBD155), encompassing
VRA, VRB and VRC, which is fused to the C terminal domain
from FeLV-A or FeLV-T Envs that encompasses the last 40
residues of RBD, PRR, Cdom and TM regions (Fig. 1B). The
design of the hybrid FeLV Envs were based on our previous
studies characterizing the functional domains of FeLV-B
envelope protein (Tailor and Kabat, 1997; Tailor et al., 2000a).
To assess the receptor-binding properties of CA and CT Envs,
and of all subsequent hybrid Envs, we first tested their ability to
interfere with FeLV-C infection. We expressed the CA and CT
Envs in feline kidney CCC cells and assessed their ability to
interfere with infection of β-galactosidase encoding FeLV-C
[lacZ(FeLV-C)] (Fig. 2A). Interference of FeLV-C infection
would give indirect evidence of the ability of CA and CT Envs to
bind to FLVCR1. As expected, feline CCC cells expressing
FeLV-C Env (C Env) were weakly susceptible to lacZ(FeLV-C)
infection, whereas feline cells expressing no Env were highly
susceptible (Fig. 2A). FeLV-C infection titers were approxi-
mately 1000-fold lower on C Env-expressing cells than titers on
parental feline cells. As shown in Fig. 2A, feline cells expressing
CA Env were 50-fold more susceptible to lacZ(FeLV-C) than C
Env-expressing cells, whereas cells expressing CT Env were
approximately 500-fold more susceptible. These findings sug-
gest that substitution of C terminal of FeLV-C Env with the
corresponding related domains from FeLV-A or FeLV-T Envs
disrupts FeLV-C interference.
To assess the minimal sequence that would restore FeLV-C
interference, we first introduced FeLV-C Cdom and TM
sequence in CA and CT Envs to respectively generate the
CAC and CTC Envs (Fig. 1B). Expression of CAC or CTC Envs
in feline cells enhanced FeLV-C interference by 10-fold when
compared to interference caused by CA and CT Envs,
respectively. Because the TM sequences from FeLV-A, -C,
and -T are highly conserved and are not involved in receptor
binding, we inferred from these results that re-introduction of
FeLV-C Cdom in CA and CT Envs was responsible for the
enhancement in FeLV-C interference. Because the C2 loop from
FeLV-A, -C and -T Envs are highly divergent (Fig. 1A), we
hypothesized that the C2 loop of FeLV-C Env was responsible
for enhancing FeLV-C interference. Thus, we generated the
CTCC2 hybrid Env, which contains the C2 loop from FeLV-C in
a CT Env backbone (Fig. 1B). Expression of CTCC2 Env in
feline cells also enhanced interference by 10-fold when
compared to interference caused by CT Env (Fig. 2A). These
results suggest that the residues within the C2 loop are critical for
enhancing virus interference.
The differences in interference properties of the hybrid
Envs could be caused by differences in the expression level
or processing of the Envs in feline cells. Thus, we analyzed
Env expression on the surface of feline cells. Detection of
surface Env expression would indicate that the hybrid Envs
are expressed and correctly processed. Surface expression of
hybrid Envs was analyzed by flow cytometry using the
C11D8 FeLV gp70-specific antibody, which recognizes the
Fig. 1. Alignment of SU protein sequence from FeLV-A, -C and -T and construction of hybrid FeLV Envs. (A) Alignment of FeLV-A, -C and -T SU protein sequence.
Identical amino acids are shaded and the respective variable regions VRA, VRB, VRC, proline rich region (PRR) and C domain are boxed and labeled. The C2
disulfide-bonded loop is also shown. The numbering of the residues begin from the start of SU. The hybrid junction represents the site used to generate specific hybrid
Envs and SUs. The glutamine residue (⁎) in the LQFTmotif was mutated to a glutamate residue to generate a LEFTmotif. Thismutation introduces a uniqueEcoRI site
in the cDNAs encoding the FeLV-A, -C and -T Envs which was used to generate hybrid FeLV Env constructs. • represents potential N-linked glycosylation sites in
FeLV-C SU that are also conserved in FeLV-A and FeLV-T SUs. ♦ represents potential N-linked glycosylation sites present in FeLV-A and FeLV-T SU that are not
present in FeLV-C SU. (B) Diagram of hybrid FeLVEnvs and SUs. Hybrid Envs contain the first 155 residues of FeLV-CRBD fused to the last 40 residues of RBD, PRR,
C domain (Cdom), and transmembrane (TM) regions from FeLV-A Env or FeLV-T Env. C Env, A Env, T Env represents FeLV-C, -A and -T Envs, respectively. CTCC2
Env was generated by replacing the FeLV-T C2 loop sequence in CT Env to FeLV-C C2 loop. The FeLV-C SU (C-SU) and all other SUs contain a double HA epitope
fused at the C terminus to allow detection of the protein inWestern blot analysis and SU binding assays. The CdomSU contains the first 16 residues of FeLV-C SU fused
to the C domain.
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shows surface expression of hybrid FeLV Envs on feline
cells. The white histogram represents cells expressing FeLVEnv, whereas the black histogram represents feline cells
expressing no Env. An increase in fluorescence denotes
increase in surface Env expression. As shown in Fig. 2B, all
Fig. 2. Interference property of hybrid FeLV Env. (A) Specific hybrid Envs were expressed in feline kidney CCC cells, which were subsequently tested for
susceptibility to β-galactosidase encoding FeLV-C pseudotype virus. Titers are mean of three independent infection experiments and are represented as colony-
forming units (CFU) per milliliter of virus medium. FeLV-C Env is represented as C Env. (B) Surface expression of hybrid FeLV Env proteins on feline CCC cells.
Env protein expression was analyzed by flow cytometry using the monoclonal C11D8 antibody followed by a fluorescein-conjugated donkey anti-mouse antibody.
Black histogram represents control feline CCC cells. White histogram represents expression of surface FeLV Env. (C) Calculation of the surface expression of FeLV
Envs on feline cells. The histogram shows a representation of Env expression on feline cells alone (grey histogram) and Env expression on feline cells expressing
hybrid FeLV Env (white histogram). Using the NIH Image J software, the difference in distance between y and z was noted and the percent surface Env expression
calculated.
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surface suggesting that they are correctly processed. Using
the NIH Image J software, we calculated the percent surface
Env expression by determining the percent change in Env
expression between cells expressing Env (Fig. 2C, distance
Z) compared to cells expressing no Env (Fig. 2C, distance
Y). We found that surface expression of CTC Env was
approximately 29–45% lower than CA, CAC, CT, and
CTCC2 surface Envs but comparable with C Env surface
expression. Taken together, because interference is governed
by the ability of Env to bind to the host receptor, we inferredfrom these results that the C2 loop residues in Cdom of
FeLV-C Env were critical for Env binding to FLVCR1.
Cdom controls efficiency of FeLV-C SU binding to FLVCR1
To provide a more direct evidence that Cdom is involved in
FeLV-C SU binding to FLVCR1, we generated soluble SU
proteins of FeLV-C, CTand CTC that were tagged with a double
hemagglutinin (HA) epitope at the C terminus (see Fig. 1B,
C-SU, CT-SU and CTC-SU). Using flow cytometry, we
measured the ability of 1 ml of SU containing culture medium
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increase in fluorescence is indicative of SU binding. As shown
in Fig. 3A, both C-SU and CTC-SU bound to FLVCR1-
expressing cells, with approximate equal level. However, we
observed a marked reduction in binding of CT-SU to MDTF/
hCR1 as shown by the reduced level of fluorescence intensity
(Fig. 3A). We determined the amount of soluble SU present in
1 ml of SU-containing medium by Western analysis of
immunoprecipitated SU proteins. As shown in Fig. 3B, we
detected approximate equivalent amounts of C, CTand CTC SU
proteins. These results suggest that the presence of FeLV-C
Cdom is critical for efficient binding of SU to FLVCR1.
Cdom is critical for FeLV-C infection of target cells
We next assessed the infection properties of β-galactosidase
encoding retroviruses bearing C, CA, CT CTC or CTCC2 Envs
on MDTF/hCR1. As expected, pseudotype virus bearing C
Env (C virus) efficiently infected MDTF/hCR1 (Fig. 4A). Virus
bearing CA Env were 300-fold less infectious than C virus,
whereas virus bearing CT Env was approximately 1,000,000-Fig. 3. Binding of soluble hybrid FeLV SU proteins to MDTF cells expressing
human FLVCR1. (A) FLVCR1-expressing MDTF cells were incubated with
(white histogram) or without (grey histogram) soluble SU proteins tagged with a
double HA epitope. Bound SU proteins were detected using monoclonal HA.11
antibody and a fluorescein-conjugated donkey anti-mouse antibody. An increase
in fluorescence intensity correlates with an increase in SU binding. C-SU
represents FeLV-C SU. (B) Western blot analysis of immunoprecipitated SU
proteins. Approximately 1 ml of medium containing soluble SU protein was
immunoprecipitated using anti-FeLV gp70 bound to a Sepharose G column. SU
proteins were analyzed by Western blot using anti-HA antibody conjugated to
horseradish peroxidase. No SU protein was detected in culture medium from
untransfected HEK293T cells.
Fig. 4. Susceptibility of MDTF cells expressing human FLVCR1 to pseudotype
virus bearing hybrid FeLVEnvs. (A) Infection titers of virus bearing FeLV-C (C) or
hybrid FeLV Envs on FLVCR1-expressing cells. Titers are average of three
infection experiments and are represented as colony-forming units (CFU) per
milliliter of virus medium. Arrow indicates no infection. (B) Western blot analysis
of virus pellets bearing hybrid Envs. A monoclonal anti-FeLV gp70 antibody was
used to detect hybrid FeLV Env proteins and a mouse anti-p30 antibody was used
to detect MLV capsid protein in virus particles. T6 represents virus particles
produced from TELCeB6 retrovirus packaging cells that do not express retrovirus
Env.fold less infectious. However, the CTC and CTCC2 viruses were
approximately 200-fold and 1000-fold, respectively, more in-
fectious than CT virus. Western blot analysis showed that all
Envs were efficiently processed and incorporated into virus
particles (Fig. 4B). We also observed that the molecular weight
of CA and CT Envs were marginally higher than C, CTC and
CTCC2 Envs. To further test the critical nature of FeLV-C C2
loop in virus infection, we generated a mutant FeLV-C Env in
which the entire C2 loop was deleted (see Fig. 1A for C2 loop).
However, we found that this Env (CΔC2) failed to be in-
corporated into virus particles (Fig. 4B), which is consistent
with the lack of infection observed on MDTF/hCR1 cells (Fig.
4A). Taken together, our results suggest that the presence of
FeLV-C Cdom or C2 loop is critical for FeLV-C infection.
Soluble Cdom binds to FLVCR1 in the absence of FeLV-C RBD
Based on the results presented above, we hypothesized that
Cdom forms a distinct domain that can bind to FLVCR1. To test
this, we generated a modified FeLV-C SU (Fig. 1B, see Cdom
SU), in which the RBD and PRR were deleted. The Cdom SU
contains the first 16 residues of FeLV-C SU fused to FeLV-C
Cdom. The design of this construct is modified from a pre-
viously reported study describing RBD deleted MLV Envs
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double HA epitope for detection in receptor binding and for
Western blot analysis. We expressed the Cdom SU in HEK293T
cells and used 1 ml of Cdom SU containing medium for binding
to MDTF/hCR1 cells. As shown in Fig. 5A, Cdom SU ex-
pression (see cell lysate) was comparable to expression of
FeLV-C SU (C-SU), and appears as a broad protein band of
approximately 40 kilodalton (kDa) molecular weight. We also
determined the level of Cdom SU protein in culture medium as
analyzed by Western analysis of immunoprecipitated SU pro-
tein from 1 ml of culture medium. We found that the level of
soluble Cdom SU was significantly lower than soluble C-SU
protein level (Fig. 5A).Fig. 5. Binding of soluble Cdom to MDTF/hCR1. (A) Western analysis showing
the HEK293 cell lysate (C.L.) fraction and culture medium (C.M.) expressing no
SU (control), C-SU (FeLV-C SU), C-RBD (FeLV-C RBD), AC-SU (hybrid SU
containing RBD155 from FeLV-A and PRR and C domain from FeLV-C) or Cdom
SU (FeLV-C C domain only). C-SU and AC-SU were isolated from C.M. by
immunoprecipitation using anti FeLV gp70 antibody on a Sepharose G column.
Soluble Cdom SU was isolated from C.M. by immunoprecipitation using anti-HA
antibody. Soluble C-RBDwas isolated from C.M. using anti-V5 antibody. Proteins
were detected byWestern blot analysis using anti-HAHRPmonoclonal antibody or
anti-V5HRP. (B) SU binding onMDTF cells andMDTF receptor-expressing cells.
Inset:Calculation of the percentage increase in SU binding. The histograms show a
representation of C-SU binding to MDTF/hCR1 cells. Target cells were either
incubated with (white) or without (grey) HA-tagged C-SU. An increase in fluo-
rescence intensity correlates with an increase in SU binding. Using the NIH Image J
software, the difference in the shift between y and z was noted and the percentage
change in SU binding calculated.Main graph: Bar graph showing the percent (%)
change in SU binding on cells incubated with SU compared to cells incubated
without SU. All SUs contain a double HA tag, whereas soluble C-RBD is tagged
with a V5 epitope. Bound SUs or RBD were detected by flow cytometry and the
percent change in SU or RBD binding was calculated as described in inset. The
percent change is average of three independent binding experiments except for
Cdom SU binding (n=4) and Cdom SU and C-RBD (n=2). Arrows represent no
detectable change in SU binding. ND denotes not determined.Using flow cytometry, we analyzed binding of HA-tagged
soluble Cdom to MDTF/hCR1 cells and to MDTF cells and
compared binding of C-SU to these cells. The inset in Fig. 5B
shows a histogram representing MDTF/hCR1 cells incubated
with C-SU (white histogram) and MDTF/hCR1 cells incubated
without C-SU (grey histogram). As described above, an in-
crease in fluorescence is indicative of SU binding. Using the
NIH Image J software, we calculated the percent change in SU
binding between cells incubated with SU (Fig. 5B inset, dis-
tance z) compared to cells incubated without SU (Fig. 5B inset,
distance y). As shown in Fig. 5B, C-SU efficiently bound to
MDTF/hCR1 cells. We also observed significant but a reduced
level of C-SU binding to MDTF cells. Binding of C-SU to
MDTF cells may be explained by the presence of the endo-
genous MDTF FLVCR1. We have previously shown that
MDTF FLVCR1 functions as a FeLV-C receptor when over
expressed (Tailor et al., 2000b). Interestingly, we observed
significant binding of Cdom SU to MDTF/hCR1, whereas no
binding was detected on MDTF cells. We next tested whether
Cdom SU binding could be enhanced in the presence of soluble
FeLV-C RBD (C-RBD). C-RBD is secreted into the culture
medium (Fig. 5A), and can bind to MDTF/hCR1 (Fig. 5C).
However, we observed a reduction in Cdom SU binding to
MDTF/hCR1 cells in the presence of C-RBD, when compared
to Cdom binding to MDTF/hCR1. We also tested Cdom binding
in the context of a full-length SU.We generated the AC-SU (Fig.
1B), which contains FeLV-A RBD155 fused to the PRR and
Cdom from FeLV-C SU, and tested its ability to bind to MDTF/
hCR1. We found that AC-SU also weakly bound to MDTF/
hCR1 cells whereas no binding was detected onMDTF cells. As
a control, we tested binding of FeLV-A 61E SU (A-SU) to
MDTF/hCR1 cells. As shown in Fig. 5B, we did not detect
binding of A-SU toMDTF/hCR1 orMDTF cells, whereas A-SU
bound efficiently to MDTF cells expressing the feline FeLV-A
receptor feTHTR1 (Mendoza et al., 2006). Taken together, our
results clearly suggest that Cdom forms a distinct receptor-
binding domain that can independently bind to FLVCR1 in the
absence of C-RBD.
Discussion
This is the first report to show that the Cdom region from
FeLV-C SU forms a novel receptor-binding domain that is
distinct from the amino terminal RBD, and which binds to its
host receptor FLVCR1 in the absence of its RBD. Our results
raise the possibility that SUs from other related gammaretro-
viruses also consist of two distinct receptor-binding domains,
RBD and Cdom, which interact with their host receptor to
initiate virus infection. In this study, we show that FeLV-CCdom
controls the efficiency of FeLV-C SU binding to FLVCR1 and is
critical for virus infection of receptor-expressing cells. Further-
more, our results suggest that residues in the C2 loop, located in
Cdom, control receptor binding and virus infection. Replace-
ment of FeLV-C PRR and Cdom with the respective domains
from the related FeLV-A or FeLV-T Envs (see Fig. 1B, CA and
CT Envs) significantly disrupts FeLV-C interference (Fig. 2A),
FeLV-C SU binding to FLVCR1 (Fig. 3A), and FeLV-C infection
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of only the FeLV-C Cdom or the C2 loop in CA or CT Envs
is sufficient to enhance interference, restore SU binding to
FLVCR1, and significantly enhance virus infection. Except for
the CΔC2 Env, all hybrid FeLV Envs tested were efficiently
expressed, processed and incorporated into virus particles
(Figs. 2B and 4B). However, we did observe some subtle but
notable differences between some FeLVEnvs. First, interference
caused by CAC Env was approximately 5-fold greater than
interference caused by CTC Env, yet both Envs have identical
sequence. This may be explained by differences in Env ex-
pression as we found surface expression of CTC Env was
approximately 30% lower than CAC Env surface expression
(Fig. 2B). Second, we found that virus bearing CTC Env, which
contains the entire FeLV-C C domain, was 5-fold less infectious
than virus bearing CTCC2 Env, which contains only the FeLV-C
C2 loop. Analysis of Env incorporation showed that CTC virus
had less Env incorporated than CTCC2 virus (Fig. 4B). However,
in addition to difference in Env incorporation, subtle variations
in Env sequence outside the C2 loop must affect infection
efficiency as observed by difference between CA and CTCC2
viruses. Sequences downstream of the C2 loop in the C domain
of FeLV-A, -C and -T Envs (Fig. 1A), although not required for
infection, have been shown to modulate infection efficiency
(Cheng et al., 2006). Finally, we found that the molecular weight
of CA and CT Envs was greater than Envs containing the FeLV-
C C2 loop (e.g. C, CTC, CTCC2 Env). The most probable
explanation for the higher molecular weight is the presence of a
potential N-linked glycosylation site in FeLV-A and FeLV-T C2
loop, which is absent in the FeLV-C C2 loop (see Fig. 1A).
The observations that CA Env can still interfere with FeLV-C
infection and that the subsequent CA virus can infect MDTF/
hCR1, albeit more weakly than FeLV-C virus, would suggest
that FeLV-A Cdom can to some extent also recognize FLVCR1.
This is not surprising because the Cdom sequence of FeLV-A
and FeLV-C SUs are highly conserved in sequence and in
length, with majority of variation confined to the C2 loop. Thus,
it is possible that in addition to C2 loop residues, other Cdom
residues that are conserved between A and C are also involved
in FLVCR1 receptor binding and infection. Taken together, our
results clearly show a critical role for FeLV-C Cdom in binding
to FLVCR1 and in virus infection, and that the C2 loop residues
control receptor binding and infection. The critical nature of the
C2 loop in virus infection is further supported by our findings
that deletion of the six residues (YLTAPR) in C2 loop of CT
Env enhances virus infection of MDTF/hCR1 cells by 1000-
fold (data not shown). Our finding that C2 loop is critical for
virus infection is consistent with a previous report showing that
insertion of FeLV-T C2 loop residues in FeLV-A Env signif-
icantly disrupts infection of cells expressing feline FeLV-A
receptor ThTR1 (Cheng et al., 2006).
It is interesting to note that despite a significant enhancement
in FeLV-C interference and virus infection when FeLV-C Cdom
or C2 loop is introduced in CT Env, the levels of interference
and virus infection are still significantly lower than respective
FeLV-C Env interference and virus infection (Figs. 2B and 4A).
These lower interference and virus infection levels may beexplained by differences in the PRR sequences of CTC and
FeLV-C Envs or differences in the last 40 residues of its RBD.
The last 40 residues of CTC RBD are derived from FeLV-T and
differ by five residues. Two of these changes are non-conserved,
which could conceivably affect interference and infection.
Alternatively, or in addition, interference and infection could be
affected by the nine amino acid difference in PRR. The PRR
from MLVs have been suggested to modulate conformational
changes in the envelope that is required for virus fusion and
infection (Lavillette et al., 2002). Similarly, the presence of
FeLV-C PRR may be required for the correct orientation of
Cdom for its optimal interaction with FLVCR1 to promote
efficient virus infection.
We show in this study that a modified FeLV-C SU
containing only Cdom is soluble and secreted into the culture
medium (Fig. 5A). Cdom SU runs as a broad protein band with
an approximate molecular weight of 40 kDa. The calculated
molecular weight of Cdom is approximately 22 kDa, which
suggests that Cdom may be heavily glycosylated. The presence
of six potential N-linked glycosylation sites in FeLV-C Cdom
(see Fig. 1A) and the broad protein band running at 40 kDa
would support Cdom to be N-linked glycosylated. We further
show in this study that Cdom binds to FLVCR1 independently
of FeLV-C RBD. Interestingly, Cdom binding to FLVCR1 is
reduced in the presence of soluble C-RBD. It is not clear from
our results how C-RBD affects Cdom binding but it is
conceivable that there may be some interaction between C-
RBD and Cdom that affects binding when the two proteins are
expressed independently. Our conclusion of a possible interac-
tion between RBD and Cdom is consistent with previous studies
suggesting an interaction between MLV RBD and its respective
Cdom (Barnett et al., 2001; Lavillette et al., 2001). It is also
interesting that we observed binding, albeit reduced, of Cdom to
FLVCR1 when expressed as a full SU containing FeLV-A RBD
(Fig. 5B, AC SU). This finding suggests the possibility that in
the context of the full SU, receptor-binding sites within Cdom
may be only partially exposed. Additional experiments are
required to fully elucidate receptor binding by Cdom in the
context of a full SU, and of the potential interaction between
RBD and Cdom.
Taken together, we propose a model of envelope–receptor
interaction for FeLV-C in which SU binding to FLVCR1 in-
volves discrete interactions of two distinct receptor-binding
domains with FLVCR1. One interaction involves RBD, which,
in agreement with previous studies (Battini et al., 1995; Battini
et al., 1992; Brojatsch et al., 1992; Rigby et al., 1992), primarily
governs receptor specificity, and a second interaction involves
Cdom that is critical for promoting virus infection. It is unclear
from these studies whether RBD and Cdom simultaneously
bind to FLVCR1 or they bind sequentially in a step-wise man-
ner. Our observation that FeLV-C Cdom binds to FLVCR1
independent of C-RBD would suggest that RBD and Cdom
simultaneously binds to FLVCR1 (see Fig. 6A). However, it is
conceivable that RBD and Cdom interact with FLVCR1 in a
two-step manner that involves an initial interaction of RBD with
the receptor, which upon conformational changes in the Env,
allows a second interaction of Cdom with the receptor (Fig. 6B).
Fig. 6. Proposed models for envelope–receptor interaction for FeLV-C infection. (A) Both the RBD (white circle) and Cdom (white square) simultaneously bind to
receptor to activate virus infection. (B) In the two-step model, RBD initially binds to receptor, which is subsequently followed by a second interaction of Cdomwith the
receptor.
280 M.A. Rey et al. / Virology 370 (2008) 273–284A two-step interaction would be intriguing, as it would show a
surprising analogy to the two-step envelope–receptor interac-
tion in HIV infection, in which the gp120 Env primarily binds to
CD4 (Dalgleish et al., 1984; Klatzmann et al., 1984) fol-
lowed by a second interaction of gp120, via the V3 loop, with
chemokine receptors that act as co-receptors (reviewed in
Hartley et al., 2005).
Relationship to other γ-retroviruses
Our envelope–receptor interaction model may be conserved
for other γ-retroviruses. A report by Donahue et al. (1991)
suggests that the replacement of FeLV-A C2 loop with FeLV-T
C2 loop reduces the ability of the subsequent virus to establish
superinfection interference, which leads to enhanced killing of
T-cells by the virus. Another report by Lavillette et al. (2002)
shows that soluble amphotropic MLV SU, which contains both
RBD and Cdom, is up to 100-fold more efficient than the
respective soluble RBD at blocking subsequent infection of
amphotropic MLV. These previous studies, in addition to studies
reporting the importance of C terminal domain of FeLV-Band PERV SUs in controlling recognition of certain re-
ceptor homologues (Boomer et al., 1997; Faix et al., 2002;
Gemeniano et al., 2006; Sugai et al., 2001), suggest that our
model of envelope–receptor interaction, involving two recep-
tor-binding domains (RBD and Cdom), is conserved for other
γ-retroviruses.
Implications for developing efficient specific cell targeting
retroviruses
Previous attempts to generate specific cell targeting retro-
viruses relied on introduction of specific ligands in the ret-
rovirus RBD to target use of alternative cell surface proteins as
receptors (reviewed by Sandrin et al., 2003). However, these
attempts have led to poor infection efficiencies. Furthermore,
some cell surface proteins are unable to mediate virus infection
despite efficient binding of modified virus to the surface protein
(Cosset et al., 1995a). We propose that γ-retroviruses have
evolved to using specific host receptor molecules that contain
the necessary determinants to allow efficient virus binding and
allow additional interactions that promote subsequent virus
281M.A. Rey et al. / Virology 370 (2008) 273–284fusion and infection. Based on our findings in this study, we
propose that generation of efficient specific cell targeting
γ-retroviruses will require a modified envelope protein that has
a fully functional RBD and Cdom, in addition to the specific
ligand. Furthermore, target cells will require expression of the
targeted receptor for specific attachment, and the expression




TELCeB6, feline kidney CCC S+L− and murineM. dunni tail
fibroblast (MDTF) cells were maintained in Dulbecco's minimal
essential medium with low glucose (1000 mg/ml) supplemented
with 10% heat-inactivated fetal bovine serum (FBS). Phoenix
ampho packaging cells (provided by Garry Nolan, Stanford
University) producing replication-defective amphotropic MLV
were maintained in Dulbecco's minimal essential medium
with high glucose (4500 mg/ml) supplemented with 10% FBS.
TELCeB6 cells are retroviral-packaging cells that do not contain
retroviral envelope genes but produce non-infectious virus
(Cosset et al., 1995b). These cells were maintained using
6 μg/ml of blasticidine to ensure selection of gag–pol-
expressing cells. MDTF cells expressing human FLVCR1 with
a HA epitope tag were generated as previously described (Brown
et al., 2006). These cells were used for FeLV SU binding and for
virus infection assays.
Construction of hybrid FeLV envelopes
cDNAs encoding hybrid FeLVenvelopes containing the first
155 residues of receptor-binding domain (RBD155) from FeLV-
C Env and the last 40 residues of RBD, proline-rich region
(PRR), C domain (Cdom) and transmembrane (TM) segment
from FeLV-A or FeLV-T Envs were generated by first
introducing an EcoRI restriction site (GAATTC) just down-
stream of cDNA encoding VRB (see Fig. 1A). Introduction of
this site caused glutamine 155 in the LQFT motif to be mutated
to a glutamate residue to give a LEFT motif. The LEFT motif is
present in all MLVEnvs (Battini et al., 1992), and has previously
been introduced in FeLV-B Env to generate functional hybrid
FeLV-B/amphotropic MLV Envs (Tailor and Kabat, 1997).
cDNA encoding FeLV-C RBD155 was amplified by PCR using
the upstream primer 5′ GGGGGGATCCATCAAGATGG
AAAGTCCAACGCACCCA-3′, which contains a BamHI
restriction site and the downstream primer 5′-CCCCCTGG-
TCTTGGAATTCACCCAGAAG-3′ containing an EcoRI site.
cDNA encoding the C-terminal region of FeLV-A, or -T Envs
encompassing the last 40 residues of RBD, PRR, Cdom and TM
was amplified by PCR from the FeLV-A 61E, and EECC (FeLV-
T) Env cDNAs (provided by Julie Overbaugh, University of
Washington, Seattle, WA). The upstream primer 5′-CTTCT-
GGGTGAATTCCAAGACCAGGGG-3′ contains an EcoRI
site where the downstream primer 5′-GGGGCTCGAGT-
CATGGTCGGTCCGAATCGTATTG-3′ contains a XhoI site.The amplified cDNAs was digested with EcoRI and XhoI and
ligated to FeLV-C RBD155 cDNA digested with BamHI and
EcoRI and cloned into the pFBneo retroviral vector (Stratagene)
digested with BamHI and XhoI. This generated the respective
CA and CT hybrid Env cDNAs. The FeLV-C Env cDNA was
also cloned into the pFBneo expression vector to give pFBneo
FeLV-C Env plasmid. cDNA encoding CAC and CTC Envs
were generated by PCR. Briefly, cDNA encoding the C domain
and TM from FeLV-C Env was amplified by PCR using pFBneo
FeLV-C Env plasmid as a template and the upstream primer 5′-
TATTACGAAGGGATTGCAATCTTAGGTAACTAC-3′,
which contains a BsBI site, and the downstream primer 5′-
GCCAGGTTTCCGGGCCTCAC-3′which primes to the 3′ end
of the multiple cloning site in pFBneo. The subsequent amplified
cDNAwas digested with BsBI and XhoI and ligated into a BsBI
and XhoI cut pFBneo CA or pFBneo CT plasmids. Digestion of
these plasmids with BsBI and XhoI removes the cDNA encoding
the FeLV-A or FeLV-T Cdom and TM sequences and allows
ligation of cDNA encoding FeLV-C Cdom and TM sequences.
The cDNA encoding CTCC2 Env (Fig. 1B) and CΔC2 Env was
also generated by PCR using mutant forward and complemen-
tary reverse primers that spanned the C2 loop cDNA sequence.
The CTCC2 Env was also cloned into the pFBneo vector. For
generation of pseudotype viruses bearing hybrid FeLV Envs, the
cDNAs encoding the hybrid FeLV Envs were cloned into the
pFBsalf retroviral expression vector (Cosset et al., 1995b),
which was subsequently introduced into the TELCeB6 retro-
viral packaging cells using the PolyFect transfection reagent
(Qiagen).
Generation of feline cells expressing hybrid FeLV Envs
Phoenix-ampho retrovirus packaging cells were transfected
with pFBneo expression constructs containing hybrid FeLV
Env cDNAs. Virus supernatant was harvested 48 h post trans-
fection, filtered with a 0.45-μm filter, and then used for in-
fection of feline CCC cells. Infected cells were selected using
G418 (1.5 mg/ml) and resistant cells were pooled and assayed
for susceptibility to β-galactosidase encoding FeLV-C Sarma
pseudotype virus (Tailor et al., 1999).
Viruses and infection studies
β-Galactosidase encoding hybrid FeLV Envs were generated
by transfection of TELCeB6 cells with the respective pFBsalf
Env expression constructs. Transfectants were selected using
phleomycin (50 μg/ml), resistant colonies were pooled, virus
supernatant harvested, filtered using a 0.45-μm filter and then
subsequently used for infection studies.
Target cells were seeded in a 24-well plate at 1×104 cells/
well one day prior to the infection study. The following day,
target cells were incubated with 1 ml of serially diluted lacZ
pseudotype virus supernatant for 4 h in the presence of
polybrene (8 μg/ml). The virus supernatant was then replaced
with fresh growth medium, and cells were allowed to incubate
for a further 2 days before X-gal (5-bromo-4-chloro-3-indoyl-β-
D-galactopyranoside) (Sigma-Aldrich, Canada) staining. LacZ
282 M.A. Rey et al. / Virology 370 (2008) 273–284pseudotype titers were determined by counting the number of
blue colony-forming units (CFU's), and titers were expressed as
the number of CFUs obtained per milliliter of undiluted virus
supernatant. Virus titer results reported are an average of three
independent experiments.
Analysis of surface expression of hybrid FeLV Envs
To confirm surface expression of FeLV-C and hybrid FeLV
Envs on feline CCC cells, we used the monoclonal C11D8 anti
FeLV gp70 antibody (provided by Custom Monoclonals
International, Sacramento, CA) (Grant et al., 1983) and a
fluorescein-conjugated donkey anti-mouse antibody for detection
of hybrid FeLV Env proteins. Briefly, approximately 5×105 cells
were dislodged from cell culture plate using a cell dissociation
buffer (Invitrogen). Cells were then incubated with the respective
C11D8 antibody followed by the secondary antibody (see above).
Cells were then analyzed by flow cytometry. An increase in
fluorescence denotes expression of SU on the surface of the feline
cells.
Analysis of Env proteins
Env proteins were also analyzed by Western blot analysis.
Target cells were dislodged from culture flask using Trypsin/
EDTA (Invitrogen) and subsequently pelleted by centrifugation
at 1000 rpm for 5 min. Lysates of cells were prepared by
incubating cells with 200 μl of cell lysis buffer (20 mM Tris–
HCl pH 7.5, 1% Triton X-100, 0.05% SDS, 5 mg/ml sodium
deoxycholate, 150 mM NaCl, 1 mM PMSF) for 10 min on ice.
The lysate was centrifuged at 13,000×g for 10 min at 4 °C to
remove cellular genomic DNA, and the supernatant was stored
at −80 °C for later use. Approximately 100 μg of total protein,
as determined by Bradford protein assay, was loaded onto a
10% SDS–polyacrylamide gel. Proteins were transferred to a
nitrocellulose membrane (Pall, Pensacola, FL) and analyzed
using a 1:500 diluted monoclonal C11D8 anti FeLV gp70
antibody, followed by a 1:1000 diluted goat anti-mouse anti-
body conjugated to HRP (Serotec). Signals were detected using
chemiluminescence reagent (Perkin-Elmer, Boston, MA),
followed by exposure to Kodak Biomax MR film. For loading
control of cell lysate samples, the nitrocellulose membrane was
incubated with 1 in 1000 diluted anti-actin monoclonal antibody
(Sigma-Aldrich) followed by 1 in 1000 diluted goat anti-mouse
HRP (Sigma-Aldrich). Env protein incorporated into lacZ
pseudotype virus particles was analyzed by first harvesting
10 ml of virus-containing supernatant, which was subsequently
filtered using a 0.45-μm filter. Virus particles were then pelleted
by centrifugation in a Beckman SW60Ti rotor at 28,500×g for
90 min at 4 °C. Virus pellets were resuspended in 100 μl of PBS
and protein concentration determined by Bradford Assay (Bio-
Rad Laboratories). Approximately 20 μg of protein was loaded
in each well of a 10% SDS–polyacrylamide gel and protein
transferred to a nitrocellulose membrane. Env protein was
visualized as described above. The MLV capsid protein, which
was used as loading control, was detected using the anti-p30
(capsid) antibody (gift from Dr. Francois-Loic Cosset).SU binding assay
For binding assay shown in Fig. 3, cDNAs encoding FeLV-C,
CT or CTC SU were amplified using the upstream primer 5′-
GGGGCTCGAGCACCATGGAAAGTCCAACGCAC




sequence encoding a double hemagglutinin (HA) epitope.
These three constructs were subsequently cloned into an
XhoI–NotI digested pFBneo vector. Soluble HA-tagged SUs
were generated by transfection of HEK293T cells with the
respective pFBneo expression constructs, and culture medium
containing the SUs was isolated 48 h post transfection. Soluble
SU containing culture medium was filtered using a 0.45-μm
filter and subsequently used for SU binding assay or stored at
−80 °C for later use. For SU binding assays shown in Fig. 5, the
respective SU encoding cDNAs were cloned into the pCS-HA
expression vector that contains a double HA sequence using
procedures previously described (Sugai et al., 2001). cDNA
encoding FeLV-C RBD containing a V5 epitope tag was
generated using the upstream primer 5′-GGGGGGGAATT-
CGGCA CCATGGAAAGTCCA-3′ and downstream primer 5′-
CCCCCCGCGGCCGCTCAGGTGCTGTCCAGGCCCAG-
CAGGGGGTTGGGGATGGGCTTGCCATCAGGTAAGAC-
TAA-3′ primer which contains the V5 epitope. FeLV-C RBD
cDNA was subsequently cloned into EcoRI–NotI digested
pFBneo retroviral expression vector. All soluble SUs and FeLV-
C RBD were expressed as described above.
Binding of soluble SUs or FeLV-C RBD to target cells was
carried out as previously described (Brown et al., 2006). Briefly,
target cells were dislodged from culture flask using a cell
dissociation buffer (Invitrogen) and approximately 1×106 cells
were incubated with 1 ml of SU containing medium in the
presence of polybrene (8 μg/ml) for 30 min at 37 °C. Cells were
then centrifuged at 4000 rpm for 3 min and then washed twice
with wash buffer (PBS containing 2% FBS). Cells were
incubated with a 1 in 200 diluted monoclonal anti HA.11 anti-
body (Covance, Berkley, CA) or monoclonal anti-V5 antibody
(Invitrogen) for 30 min at 4 °C with gentle agitation every
10 min. Cells were then subsequently washed twice with wash
buffer and then incubated for 30 min at 4 °C with a fluorescein-
conjugated donkey anti-mouse antibody. The cells were then
subsequently washed twice, fixed with 1% paraformaldehyde,
and subsequently analyzed by flow cytometry.
Immunoprecipitation of soluble SU protein
Approximately 1 ml of the HA-tagged SU or V5-tagged
FeLV-C RBD protein was precleared with 100 μg/ml of 50%
protein G-Sepharose (Amersham Biosciences) suspension for
3 h at 4 °C. The supernatants were then immunoprecipitated for
2 h at 4 °C with bound anti-gp70 antibody–bead complex for
isolation of full-length soluble SU proteins or by using bound
anti-HA or anti V5 antibody–bead complex for respective
isolation of soluble Cdom SU and soluble FeLV-C RBD.
283M.A. Rey et al. / Virology 370 (2008) 273–284Immunoprecipitates were washed three times in PBS containing
0.1% Triton X-100 and 0.1% NP40. The bound SU proteins
were eluted in 50 μl of sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS–PAGE) sample buffer and heating the
sample to 100 °C. Approximately 25 μl of sample was analyzed
by Western blot analysis using 1:100 diluted anti-HA antibody
conjugated to horseradish peroxidase (Sigma).
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